MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Anticipatory Compounding
20 questions · exam conditions
0:00
Anticipatory CompoundingQuestion 1 of 20

A 503A traditional pharmacy has been compounding a specific pain cream for a long-standing group of patients. With no current patient-specific prescriptions on hand, the pharmacist wants to compound 500 units in advance to meet an anticipated busy month. Which of the following best applies?

The pharmacy may compound 500 units anticipatorily because 503A pharmacies have broad authority to compound any product in advance.
The pharmacy may compound 500 units because the product has been successfully compounded before.
The pharmacy may compound any quantity anticipatorily as long as the product is not commercially available.
The pharmacy may compound only a limited quantity anticipatorily based on its prescription history; compounding 500 units without patient-specific prescriptions may exceed permissible anticipatory limits and approach manufacturing.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Anticipatory Compounding

Practice Anticipatory Compounding in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Anticipatory Compounding, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 503A traditional pharmacy has been compounding a specific pain cream for a long-standing group of patients. With no current patient-specific prescriptions on hand, the pharmacist wants to compound 500 units in advance to meet an anticipated busy month. Which of the following best applies?

  1. The pharmacy may compound 500 units anticipatorily because 503A pharmacies have broad authority to compound any product in advance.
  2. The pharmacy may compound 500 units because the product has been successfully compounded before.
  3. The pharmacy may compound any quantity anticipatorily as long as the product is not commercially available.
  4. The pharmacy may compound only a limited quantity anticipatorily based on its prescription history; compounding 500 units without patient-specific prescriptions may exceed permissible anticipatory limits and approach manufacturing. (correct answer)
Explanation: Under FDCA Section 503A, anticipatory compounding is permitted only in limited quantities based on a documented history of compounding that particular preparation. Compounding 500 units in the absence of patient-specific prescriptions may significantly exceed the reasonable proportion of anticipatory to patient-specific compounding and could be characterized as manufacturing, which requires FDA approval. A is incorrect because 503A pharmacies do not have broad authority for unlimited anticipatory compounding. B is incorrect because prior compounding history establishes a basis for limited anticipatory compounding, not unlimited quantities. C is incorrect because quantity limits on anticipatory compounding apply independently of whether the product is commercially available.

Question 2

A 503A pharmacy compounds a topical hormone cream anticipatorily on March 1 and assigns a 30-day BUD based on Category 1 nonsterile compounding requirements under the current USP 795 framework. A patient prescription is received on March 25, which is 24 days after compounding. Which of the following best describes whether the pharmacy may dispense this product?

  1. The pharmacy may not dispense because anticipatory compounds must be dispensed within 14 days of compounding.
  2. The pharmacy may dispense because the compound is still within its BUD at the time of dispensing; the BUD begins at the time of compounding, not at the time the prescription is received. (correct answer)
  3. The pharmacy may not dispense because the BUD for anticipatory compounds begins at the time the prescription is received, leaving only 6 days of remaining BUD.
  4. The pharmacy may dispense only if the prescriber authorizes an extension of the BUD in writing.
Explanation: The BUD for a compounded preparation begins at the time of compounding, not at the time a prescription is received. On March 25 -- 24 days after the March 1 compounding date -- the compound is still within its 30-day BUD. The pharmacy may dispense the product. A is incorrect because a 14-day limit applies under the current USP 795 framework only to specific conditions such as refrigerated Category 1 preparations; the 30-day BUD assigned for a Category 1 room-temperature preparation governs dispensing eligibility. C is incorrect because the BUD does not restart or begin at prescription receipt; it runs from the date of compounding. D is incorrect because BUDs are determined by the pharmacist based on applicable USP standards and stability data and are not subject to extension by prescriber authorization.

Question 3

A patient with a documented allergy to a specific dye used in a commercially available tablet asks her pharmacist to compound the same drug in a dye-free formulation. The drug is commercially available only in the dye-containing form. Under Section 503A, which of the following best applies?

  1. The pharmacy may not compound this product under any circumstances because the drug is commercially available.
  2. The pharmacy may compound this product only if the FDA has placed the commercially available product on the drug shortage list.
  3. The pharmacy may compound this product only if the patient's physician provides a written statement that the commercially available product is medically inappropriate.
  4. The pharmacy may compound this product if the prescriber confirms the dye-containing product is unsuitable for the patient due to a documented allergy. (correct answer)
Explanation: Under Section 503A, a compounded drug that is essentially a copy of a commercially available product is permitted when the prescribing practitioner has determined that the commercially available product is not appropriate for the identified patient -- such as when a documented allergy makes the only available formulation clinically unsuitable. The prescriber's determination of inappropriateness is a required element of this exception, not merely an inference from clinical facts; it must be made by the practitioner and documented. A is incorrect because the commercially available exclusion has recognized exceptions when the prescribing practitioner determines the commercial product is inappropriate for the patient. B is incorrect because the shortage list is not the mechanism for this exception; the prescriber-determined clinical need exception is separate and does not require shortage status. C is incorrect because while the prescriber's determination is required, the statute does not mandate a specific format such as a formal written statement; what matters is that the practitioner's determination is made and documented.

Question 4

A 503B outsourcing facility wants to compound a drug product using a bulk drug substance that is not on the FDA-approved 503B bulk drug substances list. A hospital has expressed urgent clinical need and cannot identify a commercially available alternative. Which of the following best analyzes whether the outsourcing facility may compound this product?

  1. The facility may compound the product because a hospital's clinical need automatically qualifies any drug substance for the bulk list.
  2. The facility may compound the product if it is on the FDA drug shortage list or meets interim policy criteria for nominated substances. (correct answer)
  3. The facility may compound the product immediately because clinical urgency overrides bulk substance list requirements.
  4. The facility may compound the product as long as it notifies the state board of pharmacy of the clinical justification before starting production.
Explanation: Section 503B outsourcing facilities must generally use bulk drug substances on the FDA-approved 503B bulk list. However, FDA's current policy also recognizes additional pathways: facilities may compound from bulk substances used to produce a drug appearing on FDA's current drug shortage list, and FDA's interim policy permits compounding from certain Category 1 nominated substances -- those that have been nominated and that FDA has determined warrant evaluation -- while their final list determination is pending. B correctly identifies the general framework and these additional pathways. A is incorrect because a hospital's stated clinical need does not automatically qualify a substance for any pathway; the applicable FDA policies and lists govern. C is incorrect because clinical urgency alone is not a recognized exception; the shortage pathway requires the compounded drug to appear on FDA's current shortage list, not merely that an urgent clinical need exists. D is incorrect because state board notification does not substitute for FDA bulk list compliance or any of the recognized additional pathways.

Question 5

A 503B outsourcing facility received an FDA Form 483 observation during an inspection, noting that its sterility testing program did not meet cGMP requirements. Which of the following best analyzes the facility's obligations and appropriate response?

  1. The facility may ignore the observation because Form 483 observations are advisory suggestions, not regulatory requirements.
  2. The facility must respond in writing with a corrective action plan to address the cGMP deficiencies noted in the Form 483. (correct answer)
  3. The facility should notify the state board of pharmacy and follow the board's guidance rather than responding to the FDA directly.
  4. The facility must immediately shut down all compounding operations until the FDA formally closes the observation.
Explanation: An FDA Form 483 observation documents inspectional findings that may indicate violations of applicable requirements. For a 503B outsourcing facility required to comply with cGMP, a sterility testing deficiency is a significant finding requiring a timely written corrective action plan. Failure to respond adequately can escalate to a warning letter, injunction, or seizure. A is incorrect because Form 483 observations, while not themselves legally binding orders, are serious FDA communications that require timely response to avoid escalating enforcement action. C is incorrect because the FDA -- not the state board -- is the primary regulatory authority for 503B facilities and cGMP compliance. D is incorrect because a Form 483 observation does not automatically require facility shutdown; a corrective response and remediation are the expected steps.

Question 6

During a significant drug shortage, a 503A pharmacy wants to compound large quantities of the unavailable injectable medication and distribute them to multiple healthcare facilities in the region. Which of the following applies under FDCA Section 503A?

  1. A 503A pharmacy cannot distribute compounded medications to multiple facilities without patient-specific prescriptions, even during a shortage. (correct answer)
  2. The shortage automatically authorizes expanded anticipatory compounding under 503A because patient safety is the overriding consideration.
  3. The pharmacy may distribute to multiple facilities because compounding during a shortage is exempt from all FDA requirements.
  4. The pharmacy may compound large quantities during the shortage provided it notifies the state board of pharmacy in advance.
Explanation: A drug shortage does not grant a 503A pharmacy blanket authority to compound large quantities for distribution to multiple facilities. Section 503A's patient-specific prescription requirements and quantity limitations remain in effect regardless of shortage status. Large-scale distribution to healthcare facilities requires 503B outsourcing facility registration and cGMP compliance. A correctly identifies that the shortage does not override 503A's structural limitations. B is incorrect because patient safety concern does not override FDCA regulatory requirements; the appropriate large-scale response is 503B registration. C is incorrect because FDA requirements are not categorically waived during shortages. D is incorrect because state board notification does not expand 503A authority to include large-scale multi-facility distribution.

Question 7

Under FDCA Section 503A, a traditional compounding pharmacy generally may not compound a drug that is essentially a copy of a commercially available product. Which of the following best describes the rationale for this restriction?

  1. Commercially available products are less expensive to produce, so compounding them wastes healthcare resources.
  2. Commercially available products are automatically adulterated if compounded by a pharmacy.
  3. Compounding copies of approved drugs bypasses FDA approval, undermining safety and efficacy standards. (correct answer)
  4. Commercially available drugs may not be compounded because doing so violates the manufacturer's intellectual property rights.
Explanation: The prohibition on compounding essentially a copy of a commercially available product prevents compounding pharmacies from operating as de facto manufacturers producing unapproved copies of FDA-approved drugs. Doing so would circumvent the NDA or ANDA approval process and the accompanying safety, efficacy, and quality standards. A is incorrect because the rationale is regulatory, not economic efficiency. B is incorrect because commercially available products are not automatically adulterated when compounded; the issue is regulatory classification. D is incorrect because the restriction is based on FDCA regulatory considerations, not patent or intellectual property law.

Question 8

A physician asks a 503A compounding pharmacy to prepare a bulk supply of a hormone cream for his office to administer to multiple patients over the coming months without patient-specific prescriptions. Which of the following best describes whether the pharmacy may fulfill this request?

  1. The pharmacy may not fulfill the request as 503A pharmacies require patient-specific prescriptions and cannot compound for office stock without 503B registration. (correct answer)
  2. The pharmacy may fulfill the request because a licensed physician's office is an appropriate distribution recipient for any compounded product.
  3. The pharmacy may fulfill the request because the hormone cream does not contain a controlled substance.
  4. The pharmacy may fulfill the request as long as the physician signs a statement agreeing to use the product only for his patients.
Explanation: Section 503A is designed for patient-specific compounding. Preparing a bulk supply for a physician's office stock without patient-specific prescriptions is office-use compounding, which is generally a 503B activity. Some states permit limited office-use compounding under specific conditions, but large-scale office-use compounding without patient-specific prescriptions exceeds 503A's intended scope. B is incorrect because the physician being licensed does not authorize the 503A pharmacy to provide non-patient-specific bulk supply; the regulatory classification of the activity governs. C is incorrect because the controlled substance status of the compound is irrelevant to the patient-specific versus anticipatory compounding analysis. D is incorrect because a physician's signature does not change the regulatory classification of the activity.

Question 9

A 503A pharmacy wants to expand to distribute larger batches to hospitals and clinics across the state, but finds the cGMP and FDA reporting requirements of 503B registration burdensome. The pharmacist asks whether a middle-ground option exists that allows expanded distribution without full 503B compliance. Which of the following best analyzes the situation?

  1. A middle-ground option exists: the pharmacy may distribute to up to five healthcare facilities without 503B registration as long as each facility signs a distribution agreement.
  2. A middle-ground option exists: the pharmacy may distribute to facilities within a 100-mile radius without 503B registration.
  3. There is no middle-ground option; the FDCA establishes a clear line between 503A compounding for individual patients or limited anticipatory purposes and 503B-level distribution to healthcare providers; expanded distribution to hospitals and clinics requires 503B registration and full compliance. (correct answer)
  4. A middle-ground option exists if the pharmacy obtains a state-issued wholesale distributor license, which substitutes for federal 503B registration.
Explanation: The FDCA draws a clear regulatory line between 503A and 503B activities. There is no intermediate pathway that allows pharmacy-scale compounding with expanded multi-facility distribution while avoiding 503B registration and cGMP obligations. The regulatory framework does not provide for facility-count-based, distance-based, or state-license-based workarounds. A is incorrect because no five-facility exception exists in the FDCA. B is incorrect because geographic proximity does not create an exception to 503B requirements. D is incorrect because a state wholesale distributor license does not substitute for federal 503B registration; the two are separate regulatory instruments.

Question 10

A 503A pharmacy's anticipatory compounding has grown over two years to the point where 80% of all compounding is anticipatory, 20% is patient-specific, and products are widely distributed to physician offices. Which of the following best analyzes the compliance concern?

  1. The pharmacy's operations resemble manufacturing, requiring 503B registration due to high anticipatory compounding and distribution to practitioners. (correct answer)
  2. There is no compliance concern because the pharmacy has complied with all state board licensing requirements.
  3. There is no compliance concern as long as the pharmacy can document that all compounds were eventually dispensed to patients.
  4. The compliance concern is resolved if the pharmacy converts to a model where physicians pay for anticipatory compounds upfront.
Explanation: The FDA has identified a high ratio of anticipatory to patient-specific compounding as a significant compliance concern under 503A. When 80% of compounding is anticipatory and products are distributed to physician offices rather than to individual patients with prescriptions, the pharmacy is effectively operating as a manufacturer or 503B facility without required registration and quality compliance. A correctly identifies the nature and significance of the problem. B is incorrect because state board compliance does not satisfy federal FDCA requirements; the two operate independently. C is incorrect because eventual patient dispensing does not retroactively convert manufacturing-scale activity into compliant 503A compounding. D is incorrect because the payment model is irrelevant to the regulatory classification of the compounding activity.

Question 11

A Section 503B outsourcing facility compounds a batch of a sterile analgesic solution and ships it to a hospital pharmacy without a patient-specific prescription for each unit. Which of the following most accurately describes whether this is permissible?

  1. This is not permissible because all compounded products must be accompanied by a patient-specific prescription.
  2. This is not permissible because sterile products may only be compounded under a 503A pharmacy license.
  3. This is permissible if the facility complies with cGMP, FDA registration, and reporting requirements. (correct answer)
  4. This is permissible only if the hospital has first confirmed a shortage of the commercially available product.
Explanation: Section 503B outsourcing facilities are specifically authorized to compound drug products and distribute them to healthcare providers including hospitals without patient-specific prescriptions. This is a core purpose of the 503B category, which was created to provide a pathway for anticipatory compounding for healthcare facilities while ensuring quality through cGMP and FDA oversight. A is incorrect because patient-specific prescriptions are a 503A requirement; the 503B framework was designed to operate without them. B is incorrect because sterile compounding may be performed by both 503A and 503B entities under applicable standards. D is incorrect because a shortage confirmation is not required before a 503B facility may provide products to a hospital; the 503B framework permits this activity generally.

Question 12

During an FDA-recognized drug shortage, a 503A pharmacy begins compounding a drug that is normally commercially available but is currently unavailable. Which of the following best describes the applicable regulatory considerations?

  1. A drug shortage allows compounding if 503A requirements are met, including patient-specific prescriptions, without permitting large-scale manufacturing or distribution. (correct answer)
  2. A drug shortage grants the pharmacy unlimited compounding authority because patient access to the medication is the overriding consideration.
  3. A drug shortage automatically converts the commercially available product into one that is not commercially available, removing all FDA compounding restrictions.
  4. A drug shortage requires the pharmacy to notify the DEA before beginning compounding of the shortage drug.
Explanation: During a recognized drug shortage, the FDA may exercise enforcement discretion regarding the commercially available product exclusion for 503A pharmacies, but the fundamental requirements of 503A remain in place. The pharmacy must still have patient-specific prescriptions, comply with compounding standards, and respect quantity limitations. The shortage does not convert 503A into a manufacturing license. B is incorrect because patient access concern does not override FDCA regulatory requirements; large-scale response requires 503B registration. C is incorrect because a shortage does not legally redefine a product's commercial availability status; FDA enforcement discretion is the applicable mechanism. D is incorrect because a drug shortage does not trigger DEA notification requirements; this is an FDA regulatory matter.

Question 13

A hospital pharmacy compounds a batch of 50 units of an IV antibiotic in anticipation of patient need on its infectious disease unit, based on typical weekly usage patterns. No patient-specific prescriptions have been received. Which of the following most accurately describes the hospital pharmacy's regulatory position?

  1. Hospital pharmacies are exempt from all anticipatory compounding restrictions because they operate as both pharmacy and healthcare provider.
  2. Hospital pharmacies may compound limited quantities anticipatorily for in-system use under FDA enforcement discretion, not for large-scale distribution. (correct answer)
  3. Hospital pharmacies may compound unlimited quantities anticipatorily because their formulary needs justify broad production.
  4. Hospital pharmacies must register as 503B facilities before engaging in any anticipatory compounding.
Explanation: FDA's current enforcement discretion policy recognizes that hospital pharmacies may engage in very limited, in-system anticipatory compounding for their own patient population. This discretion is conditional -- FDA's guidance has generally tied it to in-system administration and use or discard within approximately 24 hours -- and does not constitute a formal 503A authorization or blanket permission for anticipatory production. A is incorrect because hospital pharmacies are not categorically exempt from anticipatory compounding requirements; FDA's enforcement discretion is conditional, not blanket. C is incorrect because formulary needs do not authorize unlimited anticipatory compounding; the enforcement discretion framework is limited and conditional on the described parameters. D is incorrect as an absolute statement; 503B registration is required for larger-scale compounding distributed to external facilities, but FDA's enforcement discretion may accommodate limited in-system anticipatory preparation within the applicable conditions.

Question 14

A 503A pharmacy in State A ships a compounded preparation to a patient in State B pursuant to a valid patient-specific prescription. The same pharmacy also ships anticipatory preparations to physician offices in State B without patient-specific prescriptions. Which of the following analyzes the compliance difference between these two scenarios?

  1. Shipping to patients with prescriptions may be allowed; shipping anticipatory preparations without prescriptions requires 503B registration. (correct answer)
  2. Both scenarios are permissible under 503A as long as the pharmacy holds a valid license in the shipping state.
  3. Both scenarios require 503B registration because crossing state lines automatically converts a 503A activity into a 503B activity.
  4. Both scenarios are prohibited regardless of the circumstances because the FDCA does not recognize interstate compounding.
Explanation: The key distinction is the presence or absence of a patient-specific prescription. Shipping a compounded preparation to an individual patient pursuant to a valid prescription is patient-specific compounding and may be permissible under 503A with compliance with both states' laws. Shipping to physician offices without patient-specific prescriptions is office-use or large-scale anticipatory compounding, which is a 503B activity. A correctly identifies this distinction. B is incorrect because pharmacy licensing status in the shipping state does not resolve the federal regulatory classification issue. C is incorrect because crossing state lines does not automatically convert a legitimate 503A patient-specific activity into a 503B activity; the nature of the compounding is the determining factor. D is incorrect because interstate patient-specific compounding pursuant to valid prescriptions is an established and recognized practice.

Question 15

A 503A pharmacy is audited and found to have a pattern of compounding preparations essentially identical to FDA-approved commercially available products, with no documentation of patient-specific clinical need distinguishing the compounded from the commercial version. Which of the following best analyzes the compliance concern and appropriate response?

  1. There is no compliance concern because pharmacies have inherent authority to compound any drug that has a valid prescription.
  2. The compliance concern applies only if the pharmacy charges more than the commercially available product.
  3. The compliance concern is relevant only if the FDA has explicitly placed the product on its do-not-compound list.
  4. The pharmacy must document patient-specific need for compounded drugs to comply with FDCA Section 503A or stop compounding them. (correct answer)
Explanation: Section 503A prohibits compounding essentially a copy of a commercially available product without a specific, documented patient need for a different formulation. A pattern of compounding commercial copies without clinical justification documentation raises a significant compliance concern. The pharmacy must either document the clinical necessity for each patient or stop compounding those products. A is incorrect because the presence of a prescription does not override the commercially available product exclusion; clinical justification is also required. B is incorrect because pricing is irrelevant to the regulatory analysis. C is incorrect because the do-not-compound list is an additional restriction but not the sole basis for the commercially available copy prohibition; Section 503A's language governs independently.

Question 16

A physician requests that a 503A pharmacy compound a pain preparation for office use to administer to patients during office visits. State law permits limited office-use compounding under specific conditions. The FDA has indicated that office-use compounding without patient-specific prescriptions is generally inconsistent with 503A. Which of the following best analyzes the applicable legal framework?

  1. The state law permitting office-use compounding preempts the FDA's position because pharmacy practice is exclusively a state regulatory domain.
  2. The FDA's position preempts state law entirely, so office-use compounding is prohibited regardless of what state law says.
  3. Office-use compounding is permissible as long as the physician administers the compound directly to patients and does not resell it.
  4. State law allows limited office-use compounding, but pharmacies must consider FDA enforcement risks due to 503A restrictions on non-patient-specific prescriptions. (correct answer)
Explanation: The legal analysis is genuinely complex. State pharmacy practice acts may authorize certain office-use compounding under specific conditions. However, the FDA has indicated that office-use compounding without patient-specific prescriptions is generally inconsistent with 503A, creating potential federal enforcement risk even when state law permits the activity. A is incorrect because pharmacy practice is not exclusively a state regulatory domain; the FDCA also applies. B is incorrect because the FDA's position does not automatically preempt all state office-use compounding authority; the interplay requires nuanced analysis. C is incorrect because the administration model does not automatically resolve the federal regulatory concern; the applicable frameworks address the conditions of compounding, not only how the compound is used.

Question 17

A 503A compounding pharmacy has historically compounded approximately 20 units per month of a specific ophthalmic solution based on patient prescriptions. With no increase in prescriptions, the pharmacist compounds 200 units anticipatorily and distributes them to nearby ophthalmology clinics. Which of the following best describes the compliance concern?

  1. There is no compliance concern because the pharmacy has an established history of compounding this product.
  2. The compliance concern is minor because ophthalmic products are low-risk and widely needed.
  3. There is no compliance concern because the pharmacy is distributing only within the local practice area.
  4. The pharmacy compounded excess units without patient-specific prescriptions, violating 503A anticipatory compounding limits. (correct answer)
Explanation: Under 503A, anticipatory compounding must be limited in quantity based on prescription history. Compounding 200 units when historical volume is 20 per month -- without patient-specific prescriptions -- goes well beyond permissible anticipatory limits and constitutes distribution to practitioners for office use, which is a 503B activity. A is incorrect because prior compounding history authorizes only limited and proportionate anticipatory compounding, not a tenfold increase. B is incorrect because the risk level of the product does not determine whether the quantity and distribution pattern are compliant. C is incorrect because local distribution to practitioners without patient-specific prescriptions still requires 503B registration; geographic proximity does not change the regulatory classification.

Question 18

A pharmacist argues that because a patient called ahead to say she will pick up her compounded preparation later in the day, preparing the compound before the prescription arrives is patient-specific compounding rather than anticipatory compounding. Which of the following best evaluates this argument?

  1. The argument is correct because the patient has identified herself and expressed intent to pick up the prescription.
  2. The argument is correct because any compounding based on a patient's known need qualifies as patient-specific.
  3. The argument is incorrect; patient-specific compounding requires a valid prescription, not just a phone call of intent. (correct answer)
  4. The argument is correct if the physician has previously prescribed the same formula for this patient.
Explanation: Patient-specific compounding under 503A requires a valid prescription or medication order for an identified patient. A patient's phone call expressing intent to retrieve a prescription does not constitute a valid prescription. Compounding before receipt of a valid prescription remains anticipatory compounding subject to applicable limitations. A is incorrect because self-identification and expressed intent are not a valid prescription; the legal instrument is required. B is incorrect because known need does not satisfy the prescription requirement; the prescription itself is the trigger for patient-specific compounding. D is incorrect because prior prescriptions do not constitute a current valid prescription; the patient-specific designation requires a current, valid order.

Question 19

During a severe drug shortage, a state governor issues an emergency order permitting all licensed pharmacies to compound and distribute the shortage drug without patient-specific prescriptions and without 503B registration. A 503A pharmacist is asked to begin large-scale compounding under this state order. Which of the following best analyzes the compliance implications?

  1. The pharmacist should proceed because a governor's emergency order has full authority to waive all FDA requirements within the state.
  2. The pharmacist should proceed because emergency public health situations always override FDCA compounding restrictions.
  3. The pharmacist should not proceed; federal FDCA requirements remain enforceable despite the state emergency order. (correct answer)
  4. The pharmacist should proceed because the FDA will not enforce FDCA violations during a declared state emergency.
Explanation: A state governor's emergency order can waive state pharmacy law requirements within the state's authority, but it cannot waive federal FDCA requirements. Large-scale compounding and distribution to multiple healthcare facilities without 503B registration remains a potential federal FDCA violation regardless of a state emergency order. The FDA may issue its own enforcement discretion guidance during recognized emergencies, but absent such federal action, the federal regulatory risk remains. A is incorrect because state emergency orders do not have authority to waive federal statutory requirements. B is incorrect because public health emergency status does not automatically override FDCA compounding restrictions; federal waivers must come from the FDA. D is incorrect because FDA enforcement discretion must come from the FDA itself and cannot be assumed based on a state declaration.

Question 20

Which of the following most accurately distinguishes a Section 503A traditional compounding pharmacy from a Section 503B outsourcing facility?

  1. A 503A pharmacy compounds for individual prescriptions; a 503B outsourcing facility compounds in bulk without patient-specific prescriptions and registers with the FDA. (correct answer)
  2. A 503A pharmacy may compound controlled substances; a 503B outsourcing facility may not.
  3. A 503A pharmacy is subject to FDA inspection; a 503B outsourcing facility is regulated only by the state board of pharmacy.
  4. A 503A pharmacy may distribute compounds across state lines; a 503B outsourcing facility may distribute only within the state of registration.
Explanation: Section 503A provides an exemption from certain FDCA manufacturing requirements for traditional pharmacies compounding for individual patient prescriptions, with limited anticipatory compounding based on prescription history. Section 503B outsourcing facilities may compound larger quantities anticipatorily without patient-specific prescriptions but must register with the FDA and comply with cGMP. A correctly captures this core distinction. B is incorrect because controlled substance compounding authority is not the distinguishing factor between 503A and 503B. C is incorrect because 503B outsourcing facilities are subject to FDA inspection; 503A pharmacies are primarily regulated by state boards with some FDA oversight. D is incorrect because the distribution authority is effectively broader for 503B facilities, which may distribute nationwide to healthcare providers.